To Evaluate HU-045 in the Treatment of Glabellar Lines(Phase III)

Recruiting Phase 3 Interventional Study
Glabellar Lines
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Pivotal Trial This treatment is in the last trial phase before FDA approval. Prior Safety Data This treatment has already been tested in at least one earlier human trial. Healthy Volunteers Welcome You do not need to have the condition being studied to take part.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
19 – 65
Sex
Any
Trial phase
Phase 3
Study type
Interventional
Purpose
Treatment
Participants needed
312 (estimated)
Sponsor
Huons Biopharma · Industry
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial

A Multicenter, Double-blind, Randomized, Parallel, Active-controlled, Phase II Clinical Trial to Evaluate the Efficacy and Safety of HU-045 and Xeomin® in Patients With Moderate to Severe Glabellar Lines

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * 19 Years to 65 Years(Adult, Older Adult) * 2(Moderate) and/or above of Facial Wrinkle Scale (FWS) score at frown in investigator's live assessment. * Subject who signed voluntarily in informed consent form and fully understood about this clinical trial. Exclusion Criteria: *…
Contacts

Saeroarum Han

82-70-7492-6032

saeroarum@huonsbiopharma.com

CONTACT

Jiwon Kim

82-70-7492-6074

jw.kim@huonsbiopharma.com

CONTACT